Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 12/20 | 0.46 |
| ▸ | HTR7 | P34969 | 11/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.45 |
| ▸ | HTR6 | P50406 | 5/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6771866 | 0.93 | ALDH1A1 (0.58) | ALDH1A1HTR1AHTR7DRD2 | |
| SCHEMBL6766930 | 0.90 | ALDH1A1 (0.51) | ALDH1A1HTR1AHTR7LMNASLC6A2 | |
| SCHEMBL7601057 | 0.89 | ALDH1A1 (0.48) | ALDH1A1HTR1AHTR7LMNAMAPT | |
| SCHEMBL6771032 | 0.87 | ALDH1A1 (0.46) | ALDH1A1LMNASLC6A2 | |
| SCHEMBL6770007 | 0.86 | SLC6A2 (0.49) | HTR1AHTR7DRD2HTR6SLC6A2 | |
| SCHEMBL6777257 | 0.85 | ALDH1A1 (0.45) | ALDH1A1SLC6A2 | |
| SCHEMBL6770138 | 0.84 | HTR1A (0.46) | HTR1AHTR7DRD2HTR6SLC6A2 | |
| SCHEMBL6769569 | 0.84 | RAB9A (0.55) | HTR1AHTR7MAPTDRD2HTR6 | |
| SCHEMBL6771800 | 0.84 | ALDH1A1 (0.43) | ALDH1A1HTR1AHTR7LMNAMAPT | |
| SCHEMBL6769807 | 0.84 | MTTP (0.54) | SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6821967-B2 | AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-11-23 | — | — | US | disclosed |
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166637-A1 | Substituted piperazine derivatives, the preparation thereofand their use as medicaments | MTTP, CETP, CPT1A | ALDH1A1 715/4885HTR1A 1523/4885HTR7 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.